Heron Therapeutics, Inc.
HRTX
$2.26
-$0.16-6.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 24.29% | -8.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.29% | -8.92% | |||
| Cost of Revenue | -3.71% | -6.87% | |||
| Gross Profit | 44.94% | -10.38% | |||
| SG&A Expenses | -0.61% | -15.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.77% | -12.25% | |||
| Operating Income | 193.61% | 30.83% | |||
| Income Before Tax | 175.56% | 47.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 175.56% | 47.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 175.56% | 47.50% | |||
| EBIT | 193.61% | 30.83% | |||
| EBITDA | 222.62% | 33.20% | |||
| EPS Basic | 175.39% | 47.69% | |||
| Normalized Basic EPS | 214.65% | 47.76% | |||
| EPS Diluted | 175.39% | 47.69% | |||
| Normalized Diluted EPS | 214.65% | 47.76% | |||
| Average Basic Shares Outstanding | 0.21% | 0.34% | |||
| Average Diluted Shares Outstanding | 0.21% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||